Nasopharyngeal carcinoma secondary prevention: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
Line 9: | Line 9: | ||
==Secondary Prevention== | ==Secondary Prevention== | ||
EBV-associated antibodies may be helpful for secondary prevention of [[nasopharyngeal carcinoma]]. | |||
==References== | ==References== |
Revision as of 15:10, 24 September 2015
Nasopharyngeal carcinoma Microchapters |
Differentiating Nasopharyngeal carcinoma from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Nasopharyngeal carcinoma secondary prevention On the Web |
American Roentgen Ray Society Images of Nasopharyngeal carcinoma secondary prevention |
Risk calculators and risk factors for Nasopharyngeal carcinoma secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Faizan Sheraz, M.D. [2]
Overview
EBV-associated antibodies may be helpful for secondary prevention of nasopharyngeal carcinoma.
Secondary Prevention
EBV-associated antibodies may be helpful for secondary prevention of nasopharyngeal carcinoma.